Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012.

导出 OA

翻译打印收藏纠错

作者： Paul L,Hess ^[1] ; Michael J,Mirro ^[2] ; Hans-Christoph,Diener ^[3] ; John W,Eikelboom ^[4] ; Sana M,Al-Khatib ^[5] ; Elaine M,Hylek ^[6] ; Hayden B,Bosworth ^[7] ; Bernard J,Gersh ^[8] ; Daniel E,Singer ^[9] ; Greg,Flaker ^[10] ; Jessica L,Mega ^[11] ; Eric D,Peterson ^[5] ; John S,Rumsfeld ^[12] ; Benjamin A,Steinberg ^[5] ; Ajay K,Kakkar ^[13] ; Robert M,Califf ^[5] ; Christopher B,Granger ^[5] ; Atrial Fibrillation Think-Tank Participants

作者单位： Duke Clinical Research Institute, Durham, NC. Electronic address: p.hess@duke.edu. ^[1] Parkview Health System, Fort Wayne, IN. ^[2] University Hospital Essen, Essen, Germany. ^[3] Population Health Research Institute, Hamilton, Canada. ^[4] Duke Clinical Research Institute, Durham, NC. ^[5] Boston University School of Medicine, Boston, MA. ^[6] Duke Clinical Research Institute, Durham, NC; Durham Veterans Affairs Medical Center, Durham, NC. ^[7] Mayo Clinic College of Medicine, Rochester, MN. ^[8] Massachusetts General Hospital, Boston, MA. ^[9] University of Missouri, Columbia, MO. ^[10] Brigham and Women's Hospital, Boston, MA. ^[11] VA Eastern Colorado Health Care System, Denver, CO. ^[12] Thrombosis Research Institute and University College London, London, United Kingdom. ^[13]